• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Merus N.V.

    3/25/24 5:22:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    SC 13G 1 tm249746d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*

     

    MERUS N.V.

    (Name of Issuer)

     

    Common Shares, nominal value €0.09 per share

    (Title of Class of Securities)

     

    N5749R100

    (CUSIP Number)

     

    March 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. N5749R10013GPage 2 of 5 Pages

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Incyte Corporation

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
       

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.   SOLE VOTING POWER
     
    4,004,544
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    4,004,544*
      8.   SHARED DISPOSITIVE POWER
     
    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,004,544

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
     
       
    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.9%*

       
    12.  

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

       

     

    *See footnotes to Item 4 below.

     

     

     

     

    CUSIP No. N5749R10013GPage 3 of 5 Pages

     

    Item 1(a) Name of Issuer:
       
      Merus N.V. (“Merus”)
       
    Item 1(b) Address of Issuer’s Principal Executive Offices:
       
      Uppsalalaan 17, 3584 CT Utrecht, The Netherlands
       
    Item 2(a) Name of Person Filing:
       
      Incyte Corporation (“Incyte”)
       
    Item 2(b) Address of the Principal Business Office or, if none, Residence:
       
      1801 Augustine Cut-Off, Wilmington, DE 19803
       
    Item 2(c) Citizenship:
       
      Delaware
       
    Item 2(d) Title of Class of Securities:
       
      common shares, nominal value €0.09 per share (“Common Shares”)
       
    Item 2(e) CUSIP Number:
       
      N5749R100
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
       
    Item 4. Ownership
       
      (a) Amount beneficially owned: 4,004,544 shares
       
      (b) Percent of class: 6.9%(1)
       
      (c) Number of shares as to which the person has: 
       
        (i) Sole power to vote or to direct the vote: 4,004,544 shares
       
        (ii) Shared power to vote or to direct the vote: 0
       
        (iii) Sole power to dispose or to direct the disposition of:  4,004,544 shares (2)
       
        (iv) Shared power to dispose or to direct the disposition of: 0

     

     

     

     

    CUSIP No. N5749R10013GPage 4 of 5 Pages

     

    (1)The ownership percentage of Incyte has been calculated based on a total of 57,878,284 Common Shares outstanding as of February 22, 2024, as disclosed by Merus in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2024.

     

    (2)Incyte has reevaluated its investment in Merus and, in addition to no longer holding the Common Shares reported in this Schedule 13G (the “Shares”) with a purpose or effect of changing or influencing control of Merus or in connection with or as a participant in any transaction having that purpose or effect, Incyte expects to make sales of the Shares over time as market conditions permit in the open market or in private transactions. Incyte may, however, decide to discontinue any such sales or make purchases of Common Shares in the future either in the open market or in private transactions depending on various factors, including, among other things, Incyte’s evaluation of the market for the Common Shares, stock market and general economic conditions, Merus’s business, prospects and financial condition, other opportunities available to Incyte, and other future developments.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    CUSIP No. N5749R10013GPage 5 of 5 Pages

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 25, 2024

     

      INCYTE CORPORATION
         
      By: /s/ Sheila A. Denton
        Sheila A. Denton
        Executive Vice President and General Counsel

     

     

     

     

    Get the next $MRUS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    11/2/2023$45.00Buy
    Canaccord Genuity
    8/21/2023Outperform
    TD Cowen
    More analyst ratings

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Merus with a new price target

      Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

      2/13/25 8:09:56 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Merus with a new price target

      Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00

      2/7/25 8:26:14 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Merus with a new price target

      Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00

      11/21/24 7:35:31 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 6, 2024 - FDA Roundup: December 6, 2024

      For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

      12/6/24 3:09:02 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • COO & GC Silverman Peter B. exercised 34,000 shares at a strike of $18.61 and sold $1,793,840 worth of shares (34,000 units at $52.76) (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      6/24/25 4:00:05 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pucci Paolo

      4 - Merus N.V. (0001651311) (Issuer)

      5/27/25 8:00:11 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gowen Maxine

      4 - Merus N.V. (0001651311) (Issuer)

      5/27/25 8:00:08 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    SEC Filings

    See more
    • SEC Form 424B5 filed by Merus N.V.

      424B5 - Merus N.V. (0001651311) (Filer)

      6/5/25 6:07:14 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Merus N.V.

      424B5 - Merus N.V. (0001651311) (Filer)

      6/3/25 4:05:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Merus N.V.

      8-K - Merus N.V. (0001651311) (Filer)

      5/29/25 8:30:21 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merus N.V. Announces Pricing of Public Offering of Common Shares

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the "Offer Shares"). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the "Option Shares" and together with the Offer Shares, the "Shares"). The gross proceeds from the offering, before deducting underw

      6/4/25 12:13:23 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus N.V. Announces Proposed Public Offering of Common Shares

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the launch of a proposed underwritten public offering of its common shares (the "Offer Shares"). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the "Option Shares" and together with the Offer Shares, the "Shares"). The offering is subject to market co

      6/3/25 4:05:00 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus to Present at Upcoming Investor Conferences

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ETJefferies Global Healthcare Conference: Wednesday, June 4 at 3:10 p.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived

      5/27/25 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

      7/1/24 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

      6/15/23 7:47:06 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

      1/25/22 4:30:00 PM ET
      $INCY
      $MRUS
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRUS
    Financials

    Live finance-specific insights

    See more
    • Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

      -  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be

      5/22/25 5:30:00 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 4:05:20 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 1:34:01 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 8:54:46 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care